A 52 Week Open Label Trial of Memantine for Frontotemporal Lobar Degeneration
Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
This is a 52-week, multicenter, open label trial of memantine (Namenda) for frontotemporal
lobar degeneration (FTLD). The goal is to determine the safety and tolerability of this
FDA-approved medication for Alzheimer's Disease in patients with FTLD. Secondary outcome
measures include cognitive batteries, rating scales for activities of daily living and
neuropsychiatric symptoms. All patients receive the FDA-approved dose of this medication for
Alzheimer's disease.